PTCT,NXGL Stock Price and Quote

Dollar change +0.93
Percentage change 2.06	%

Peers: SRPT ALNY BIIB VRTX IONS RARE EXEL ARWR BLUE VYGR

| Held by: VTI IWM VB VXF VBK XBI IWO IBB SCHA VTWO

Index	RUT	P/E	-	EPS (ttm)	-5.94	Insider Own	2.23%	Shs Outstand	76.95M	Perf Week	-0.06%
Market Cap	3.56B	Forward P/E	-	EPS next Y	-1.46	Insider Trans	-12.13%	Shs Float	75.41M	Perf Month	2.03%
Income	-453.20M	PEG	-	EPS next Q	-0.55	Inst Own	101.66%	Short Float	5.62%	Perf Quarter	14.01%
Sales	900.66M	P/S	3.95	EPS this Y	46.43%	Inst Trans	-2.05%	Short Ratio	5.93	Perf Half Y	39.72%
Book/sh	-13.70	P/B	-	EPS next Y	67.47%	ROA	-29.22%	Short Interest	4.24M	Perf Year	63.88%
Cash/sh	13.14	P/C	3.51	EPS next 5Y	-	ROE	-	52W Range	23.58 - 54.16	Perf YTD	2.24%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-24.94%	ROI	-	52W High	-14.79%	Beta	0.62
Dividend TTM	-	Quick Ratio	2.04	Sales past 5Y	32.36%	Gross Margin	77.26%	52W Low	95.72%	ATR (14)	2.01
Dividend Ex-Date	-	Current Ratio	2.10	EPS Y/Y TTM	31.43%	Oper. Margin	-14.18%	RSI (14)	54.71	Volatility	4.01% 4.38%
Employees	995	Debt/Eq	-	Sales Y/Y TTM	12.84%	Profit Margin	-50.32%	Recom	2.20	Target Price	58.14
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	21.40%	Payout	-	Rel Volume	0.61	Prev Close	45.22
Sales Surprise	15.36%	EPS Surprise	8.61%	Sales Q/Q	0.11%	Earnings	Nov 07 AMC	Avg Volume	715.22K	Price	46.15
SMA20	2.83%	SMA50	1.57%	SMA200	23.08%	Trades		Volume	434,674	Change	2.06%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-13-24	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$45 → $67
Dec-03-24	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$39 → $63
Oct-10-24	Resumed	Raymond James	Mkt Perform
Sep-04-24	Initiated	Robert W. Baird	Outperform	$44
Aug-26-24	Resumed	UBS	Buy	$47
May-20-24	Upgrade	Raymond James	Underperform → Mkt Perform
Dec-19-23	Downgrade	Morgan Stanley	Equal-Weight → Underweight	$28
Dec-08-23	Initiated	Wells Fargo	Overweight	$37
Oct-30-23	Upgrade	Oppenheimer	Perform → Outperform	$165
Oct-27-23	Downgrade	Citigroup	Neutral → Sell	$29 → $17
Oct-06-23	Downgrade	Truist	Buy → Hold	$45 → $25
Sep-18-23	Downgrade	Citigroup	Buy → Neutral	$55 → $28
Sep-15-23	Downgrade	Raymond James	Outperform → Underperform
Mar-17-23	Initiated	SVB Securities	Market Perform	$48
Dec-14-22	Initiated	Goldman	Sell	$35
Sep-12-22	Initiated	Jefferies	Buy	$62
Sep-09-22	Initiated	Morgan Stanley	Equal-Weight	$54
Sep-01-22	Initiated	Citigroup	Buy	$70
Apr-04-22	Resumed	Cantor Fitzgerald	Overweight	$64 → $63
Oct-18-21	Downgrade	BofA Securities	Neutral → Underperform	$38

Show Previous Ratings

Jan-13-25 04:30PM	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -5.09%
09:00AM	PTC Therapeutics Provides Update on Commercial Performance and RandD Pipeline at 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
09:00AM	PTC Therapeutics Provides Update on Commercial Performance and R&D Pipeline at 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-23-24 08:00AM	PTC Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-19-24 08:00AM	PTC Therapeutics Announces Vatiquinone NDA Submission to FDA for the Treatment of Children and Adults Living with Friedreich Ataxia (PR Newswire)
04:30PM	Loading…
Dec-17-24 04:30PM	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Dec-10-24 05:11PM	UniQure Stock Doubles After Striking A Deal With The FDA For Huntington's Drug (Investor's Business Daily)
09:34AM	UniQure Stock Nearly Doubles After Striking A Deal With The FDA For Huntington's Drug (Investor's Business Daily)
Dec-04-24 07:15AM	PTC Therapeutics price target raised to $71 from $47 at UBS (TipRanks)
Dec-03-24 04:42AM	Novartis and PTC Therapeutics link to develop Huntingtons therapy (Pharmaceutical Technology)
Dec-02-24 04:21PM	PTC Therapeutics Scores A $2.9 Billion Novartis Deal And Tops Profit-Taking Zone (Investor's Business Daily) +18.66%
12:58PM	PTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For Huntington's Program (Benzinga)
12:40PM	PTC Therapeutics Stock Soars on Novartis Licensing Agreement (Investopedia)
11:29AM	Novartis' $2.9 Billion Huntington's Bet Sends PTC Stock Soaring Over 14% (GuruFocus.com)
07:00AM	PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program (PR Newswire)
05:56AM	Loading…
05:56AM	Novartis wagers billions of dollars on PTC Huntingtons drug (BioPharma Dive)
Nov-28-24 07:11AM	PTC Therapeutics to sell Priority Review Voucher for $150M (TipRanks)
Nov-27-24 10:12AM	PTC Therapeutics ALS drug fails to meet endpoints as trials shut down (Clinical Trials Arena)
07:51AM	PTC Therapeutics Ends Utreloxastat Development After Rare Neurodegenerative Disease Trial Misses Goal, Analyst Maintains Outperform With Focus On Sepiapterin, Huntington's Programs (Benzinga)
07:00AM	PTC Therapeutics Enters into Agreement to Sell Priority Review Voucher for $150 Million (PR Newswire)
05:38AM	Kronos, Idorsia plan layoffs; PTC shelves ALS drug (BioPharma Dive)
Nov-26-24 04:30PM	PTC Therapeutics Announces Topline Results of CardinALS Trial of Utreloxastat in ALS Patients (PR Newswire) +7.02%
Nov-25-24 04:30PM	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Nov-14-24 01:46PM	FDA Grants Conditional Approval For PTC Therapeutics' Gene Therapy As First Ever With Direct Administration In Brain (Benzinga)
10:00AM	FDA grants accelerated approval for PTCs AADC deficiency gene therapy (Pharmaceutical Technology)
06:28AM	PTC wins US approval of gene therapy for fatal enzyme disorder (BioPharma Dive)
Nov-13-24 06:02PM	PTC Therapeutics Announces FDA Approval of AADC Deficiency Gene Therapy (PR Newswire)
Nov-08-24 10:05AM	PTC Therapeutics Inc (PTCT) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ... (GuruFocus.com)
Nov-07-24 06:30PM	PTC Therapeutics (PTCT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
05:25PM	PTC Therapeutics (PTCT) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:23PM	Loading…
04:23PM	PTC Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results (PR Newswire)
Nov-06-24 09:15AM	Unlocking Q3 Potential of PTC Therapeutics (PTCT): Exploring Wall Street Estimates for Key Metrics (Zacks) +5.65%
07:11AM	PTC Therapeutics Inc (PTCT) Q3 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Nov-04-24 04:30PM	PTC Therapeutics to Participate at Upcoming Investor Conferences (PR Newswire)
Nov-01-24 06:06AM	Regeneron battles Wall Street uncertainty; Madrigal extends fast launch of MASH drug (BioPharma Dive)
Oct-30-24 07:00AM	PTC Therapeutics Announces FDA Acceptance of Translarna NDA Resubmission (PR Newswire)
Oct-25-24 04:30PM	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Oct-24-24 07:00AM	PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2024 Financial Results (PR Newswire)
Oct-18-24 03:01PM	State Street Corp's Strategic Acquisition in PTC Therapeutics Inc (GuruFocus.com) +5.65%
07:04AM	PTC rebuffed again by EMA; Novartis licenses China-based biotechs cancer drug (BioPharma Dive)
06:30AM	CHMP Maintains Negative Opinion on Translarna Reexamination (PR Newswire)
Oct-17-24 10:01AM	Will PTC Therapeutics (PTCT) Report Negative Q3 Earnings? What You Should Know (Zacks)
Oct-14-24 04:30PM	PTC Therapeutics Announces FDA Target Regulatory Action Date for Sepiapterin and Lancet Publication of Phase 3 Trial Results (PR Newswire)
Oct-09-24 05:54PM	PTC Therapeutics Inc (PTCT) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
03:07PM	PTC Therapeutics (PTCT) Surges 16.5%: Is This an Indication of Further Gains? (Zacks)
Oct-08-24 08:00AM	PTC Therapeutics Announces Positive Results from Long-Term Treatment Studies and Updates on Regulatory Progress for Vatiquinone Friedreich Ataxia Program (PR Newswire) +16.52%
Oct-04-24 05:17AM	3 Top Stocks That Could Still Rocket Higher in 2024 (Motley Fool)
Oct-01-24 09:00AM	PTC Therapeutics Announces FDA Acceptance for Filing of NDA for Sepiapterin for the Treatment of Pediatric and Adult Phenylketonuria Patients (PR Newswire)
05:00AM	5 FDA decisions to watch in the fourth quarter (BioPharma Dive)
Sep-26-24 08:00AM	FDA Grants Fast Track Designation to PTC518 Huntington's Disease Program (PR Newswire)
Sep-12-24 04:30PM	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Aug-28-24 04:30PM	PTC Therapeutics to Participate at Upcoming Investor Conferences (PR Newswire)
Aug-19-24 03:33PM	PTC Therapeutics Stock Earns RS Rating Upgrade To 83 (Investor's Business Daily)
Aug-08-24 05:15PM	PTC Therapeutics (PTCT) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:09PM	PTC Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results (PR Newswire)
Aug-06-24 09:15AM	Unlocking Q2 Potential of PTC Therapeutics (PTCT): Exploring Wall Street Estimates for Key Metrics (Zacks)
Jul-30-24 08:00AM	PTC Therapeutics Announces Sepiapterin NDA Submission to FDA (PR Newswire)
Jul-25-24 04:30PM	PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2024 Financial Results (PR Newswire)
10:02AM	Will PTC Therapeutics (PTCT) Report Negative Q2 Earnings? What You Should Know (Zacks)
Jul-01-24 08:00AM	PTC Therapeutics (PTCT) Down on Negative CHMP Opinion on DMD Drug (Zacks)
Jun-28-24 04:08PM	PTC's Journey Of 'Twist And Doubt' Continues With Another Rejection; Shares Tumble (Investor's Business Daily) -11.77%
08:53AM	PTC Therapeutics Tumbles After European Regulators Reject Its Drug Again (Investor's Business Daily)
07:49AM	PTC faces another Duchenne drug rejection; Coherus sells Humira biosimilar (BioPharma Dive)
06:00AM	CHMP Issues Negative Opinion on Translarna Following European Commission Request for Review (PR Newswire)
Jun-24-24 04:44AM	PTC Therapeutics (PTCT) Soars 9.7%: Is Further Upside Left in the Stock? (Zacks)
Jun-21-24 04:30PM	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) +9.70%
Jun-20-24 08:19AM	FDA lifts hold on PTC Huntingtons disease trial (BioPharma Dive) -6.54%
06:30AM	Interim PIVOT-HD Results Demonstrate Evidence of Favorable CNS Biomarker and Clinical Effects at Month 12 in Huntington's Disease Patients (PR Newswire)
Jun-04-24 06:00AM	The 3 Most Undervalued Biotech Stocks to Buy in June 2024 (InvestorPlace)
May-29-24 08:00AM	PTC Therapeutics to Participate at Upcoming Investor Conference (PR Newswire)
May-28-24 08:30AM	PTC Therapeutics Announces Validation of Sepiapterin European MAA (PR Newswire)
May-25-24 02:41AM	Insider Sale: Director Jerome Zeldis Sells 20,000 Shares of PTC Therapeutics Inc (PTCT) (GuruFocus.com)
May-21-24 12:26PM	PTC Therapeutics (PTCT) Up as EC Returns CHMP Opinion on DMD Drug (Zacks)
10:34AM	Goldman Sachs Adjusts PTC Therapeutics Price Target to $32 From $18, Maintains Sell Rating (MT Newswires)
May-20-24 04:05PM	PTC Therapeutics Stock Soars As Its Biggest Drug 'Lives To Fight Another Day' (Investor's Business Daily) +21.23%
12:36PM	Raymond James Upgrades PTC Therapeutics to Market Perform From Underperform (MT Newswires)
12:20PM	PTC Therapeutics Announces European Commission Returns Translarna Opinion to CHMP For Re-evaluation (PR Newswire)
08:57AM	Sector Update: Health Care (MT Newswires)
08:45AM	PTC Therapeutics Says European Commission Seeking Review of Negative Opinion on Translarna (MT Newswires)
07:45AM	European Commission, in unprecedented move, declines to revoke approval of PTC Duchenne drug (BioPharma Dive)
May-14-24 09:10AM	Sector Update: Health Care Stocks Steady Premarket Tuesday (MT Newswires)
08:51AM	Sector Update: Health Care (MT Newswires)
08:26AM	PTC Therapeutics Gets FDA Priority Review for Upstaza Biologics License Application (MT Newswires)
07:30AM	PTC Therapeutics Announces FDA Acceptance and Priority Review of the BLA for Upstaza (PR Newswire)
May-02-24 08:00AM	PTC Therapeutics to Participate at Upcoming Investor Conferences (PR Newswire)
May-01-24 02:45PM	PTC Therapeutics Stock Sees IBD RS Rating Climb To 72 (Investor's Business Daily) +6.25%
Apr-30-24 12:25PM	PTC Therapeutics, Inc. (NASDAQ:PTCT) Q1 2024 Earnings Call Transcript (Insider Monkey)
Apr-29-24 06:11AM	Morgan Stanley Upgrades PTC Therapeutics to Equalweight From Underweight, Adjusts PT to $30 From $28 (MT Newswires) +12.50%
Apr-26-24 03:57PM	Sector Update: Health Care Stocks Edge Higher Late Afternoon (MT Newswires) +12.08%
11:16AM	PTC Therapeutics Shares Rise After Better-Than-Expected Q1 Results (MT Newswires)
07:11AM	Q1 2024 PTC Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
03:35AM	PTC Therapeutics Inc (PTCT) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth ... (GuruFocus.com)
Apr-25-24 08:56PM	PTCT Stock Earnings: PTC Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
08:00PM	Compared to Estimates, PTC Therapeutics (PTCT) Q1 Earnings: A Look at Key Metrics (Zacks)
05:39PM	PTC Therapeutics Q1 2024 Earnings: A Detailed Financial Review (GuruFocus.com)
04:53PM	PTC Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	PTC Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results (PR Newswire)
Apr-23-24 04:30PM	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)

PTC Therapeutics, Inc. is a biopharmaceutical company, which focuses on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The company was founded by Allan Steven Jacobson and Stuart Walter Peltz on March 31, 1998 and is headquartered in Warren, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Utter Christine Marie	SVP, CHIEF ACCOUNTING OFFICER	Jan 08 '25	Sale	44.50	1,662	73,959	64,321	Jan 10 05:20 PM
Utter Christine Marie	SVP, CHIEF ACCOUNTING OFFICER	Jan 07 '25	Sale	45.34	1,291	58,534	65,983	Jan 10 05:20 PM
Pauwels Eric	CHIEF EXECUTIVE OFFICER	Jan 08 '25	Sale	44.50	2,136	95,052	86,805	Jan 10 05:20 PM
Pauwels Eric	CHIEF EXECUTIVE OFFICER	Jan 07 '25	Sale	45.34	1,599	72,499	88,941	Jan 10 05:20 PM
Klein Matthew B.	CHIEF EXECUTIVE OFFICER	Jan 08 '25	Sale	44.50	2,402	106,889	283,830	Jan 10 05:20 PM
Klein Matthew B.	CHIEF EXECUTIVE OFFICER	Jan 07 '25	Sale	45.34	2,142	97,118	286,232	Jan 10 05:20 PM
Golden Lee Scott	EVP & CHIEF MEDICAL OFFICER	Jan 08 '25	Sale	44.50	1,198	53,311	78,651	Jan 10 05:20 PM
Golden Lee Scott	EVP & CHIEF MEDICAL OFFICER	Jan 07 '25	Sale	45.34	810	36,725	79,849	Jan 10 05:20 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Jan 08 '25	Sale	44.50	1,998	88,911	106,848	Jan 10 05:20 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Jan 07 '25	Sale	45.34	1,543	69,960	108,846	Jan 10 05:20 PM
Almstead Neil Gregory	CHIEF TECHNICAL OPS OFFICER	Jan 08 '25	Sale	44.50	1,552	69,064	103,231	Jan 10 05:20 PM
Almstead Neil Gregory	CHIEF TECHNICAL OPS OFFICER	Jan 07 '25	Sale	45.34	1,265	57,355	104,783	Jan 10 05:20 PM
Almstead Neil Gregory	CHIEF TECHNICAL OPS OFFICER	Jan 08 '25	Sale	44.50	107	4,762	5,975	Jan 10 05:20 PM
Almstead Neil Gregory	CHIEF TECHNICAL OPS OFFICER	Jan 07 '25	Sale	45.34	55	2,494	6,082	Jan 10 05:20 PM
Bell William F. Jr.	Former Director	Jan 10 '25	Proposed Sale	44.57	6,666	297,104		Jan 10 04:44 PM
Almstead Zheng Yang	Member of immediate family of	Jan 08 '25	Proposed Sale	44.50	107	4,761		Jan 08 05:29 PM
Golden Lee Scott	Officer	Jan 08 '25	Proposed Sale	44.50	1,198	53,311		Jan 08 05:19 PM
Almstead Neil Gregory	Officer	Jan 08 '25	Proposed Sale	44.50	1,552	69,064		Jan 08 05:18 PM
Pauwels Eric	Officer	Jan 08 '25	Proposed Sale	44.50	2,136	95,052		Jan 08 05:06 PM
Klein Matthew B.	Officer	Jan 08 '25	Proposed Sale	44.50	2,402	106,889		Jan 08 05:01 PM
Utter Christine Marie	Officer	Jan 08 '25	Proposed Sale	44.50	1,662	73,959		Jan 08 04:51 PM
Boulding Mark Elliott	Officer	Jan 08 '25	Proposed Sale	44.50	1,998	88,911		Jan 08 04:46 PM
Golden Lee Scott	Officer	Jan 07 '25	Proposed Sale	45.34	810	36,723		Jan 07 04:42 PM
Boulding Mark Elliott	Officer	Jan 07 '25	Proposed Sale	45.34	1,543	69,956		Jan 07 04:38 PM
Klein Matthew B.	Officer	Jan 07 '25	Proposed Sale	45.34	2,142	97,113		Jan 07 04:31 PM
Pauwels Eric	Officer	Jan 07 '25	Proposed Sale	45.34	1,599	72,495		Jan 07 04:31 PM
Almstead Neil Gregory	Officer	Jan 07 '25	Proposed Sale	45.34	1,265	57,352		Jan 07 04:24 PM
Almstead Zheng Yang	Member of immediate family of	Jan 07 '25	Proposed Sale	45.34	55	2,494		Jan 07 04:24 PM
Utter Christine Marie	Officer	Jan 07 '25	Proposed Sale	45.34	1,291	58,531		Jan 07 04:13 PM
Klein Matthew B.	CHIEF EXECUTIVE OFFICER	Dec 31 '24	Sale	45.16	8,279	373,880	217,528	Jan 03 05:21 PM
Klein Matthew B.	Director	Dec 31 '24	Proposed Sale	45.16	8,279	373,876		Dec 31 03:25 PM
Almstead Neil Gregory	CHIEF TECHNICAL OPS OFFICER	Dec 02 '24	Option Exercise	51.00	69,550	3,547,050	153,158	Dec 04 05:20 PM
Almstead Neil Gregory	CHIEF TECHNICAL OPS OFFICER	Dec 02 '24	Option Exercise	51.00	2,060	105,060	6,636	Dec 04 05:20 PM
Almstead Neil Gregory	CHIEF TECHNICAL OPS OFFICER	Dec 02 '24	Sale	52.06	69,550	3,620,895	86,202	Dec 04 05:20 PM
Almstead Neil Gregory	CHIEF TECHNICAL OPS OFFICER	Dec 02 '24	Sale	51.97	2,060	107,063	4,576	Dec 04 05:20 PM
ZELDIS JEROME B	Director	Dec 02 '24	Option Exercise	40.93	24,000	982,320	26,500	Dec 04 05:20 PM
ZELDIS JEROME B	Director	Dec 02 '24	Sale	51.50	24,000	1,235,897	14,500	Dec 04 05:20 PM
Utter Christine Marie	SVP, CHIEF ACCOUNTING OFFICER	Dec 02 '24	Option Exercise	51.00	17,800	907,800	67,123	Dec 04 05:20 PM
Utter Christine Marie	SVP, CHIEF ACCOUNTING OFFICER	Dec 02 '24	Sale	51.77	17,800	921,585	52,428	Dec 04 05:20 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Dec 02 '24	Option Exercise	51.00	85,600	4,365,600	176,029	Dec 04 05:20 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Dec 03 '24	Option Exercise	33.02	10,308	340,370	100,109	Dec 04 05:20 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Dec 02 '24	Sale	52.26	85,600	4,473,280	92,389	Dec 04 05:20 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Dec 03 '24	Sale	53.26	10,308	549,055	92,389	Dec 04 05:20 PM
Boulding Mark Elliott	Officer	Dec 03 '24	Proposed Sale	53.26	10,308	549,041		Dec 03 04:52 PM
Almstead Zheng Yang	Member of immediate family of	Dec 02 '24	Proposed Sale	51.98	2,060	107,070		Dec 02 05:16 PM
Almstead Neil Gregory	Officer	Dec 02 '24	Proposed Sale	52.06	69,550	3,620,604		Dec 02 04:48 PM
Utter Christine Marie	Officer	Dec 02 '24	Proposed Sale	51.77	17,800	921,544		Dec 02 04:37 PM
ZELDIS JEROME B	Director	Dec 02 '24	Proposed Sale	51.50	24,000	1,235,914		Dec 02 04:31 PM
Boulding Mark Elliott	Officer	Dec 02 '24	Proposed Sale	52.26	85,600	4,473,211		Dec 02 04:26 PM
Gravier Pierre	CHIEF FINANCIAL OFFICER	Jul 16 '24	Sale	34.02	2,269	77,200	53,531	Jul 18 05:20 PM
ZELDIS JEROME B	Director	May 22 '24	Option Exercise	26.42	20,000	528,400	34,500	May 24 05:20 PM
ZELDIS JEROME B	Director	May 22 '24	Sale	38.24	20,000	764,800	14,500	May 24 05:20 PM
Golden Lee Scott	EVP & CHIEF MEDICAL OFFICER	May 07 '24	Sale	32.82	175	5,744	59,813	May 08 05:20 PM
Klein Matthew B.	CHIEF EXECUTIVE OFFICER	Apr 19 '24	Sale	24.89	3,361	83,669	225,807	Apr 22 05:20 PM
Pauwels Eric	CHIEF EXECUTIVE OFFICER	Apr 17 '24	Sale	25.14	787	19,781	67,694	Apr 19 05:20 PM
Klein Matthew B.	CHIEF EXECUTIVE OFFICER	Apr 17 '24	Sale	25.14	1,307	32,851	229,168	Apr 19 05:20 PM
Golden Lee Scott	EVP & CHIEF MEDICAL OFFICER	Apr 02 '24	Sale	28.37	526	14,923	59,988	Apr 04 05:16 PM

PTCT

PTC Therapeutics Inc

NXGL

Nexgel Inc

Upgrade your FINVIZ experience